Allogene Therapeutics, Inc. (ALLO)
Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company working on engineered allogeneic CAR T cell therapies—a class of treatments that uses genetically modified immune cells to attack disease. Based in South San Francisco, the company was founded in 2017 and focuses on developing off-the-shelf cellular therapies that could be administered to multiple patients, as opposed to individually manufactured treatments. Its technology platform combines protein engineering, gene editing, and proprietary T cell manufacturing to create “off-the-shelf” CAR T candidates without the personalized production constraints of conventional approaches.
The company’s pipeline centers on three therapeutic areas: large B-cell lymphoma (an aggressive blood cancer), autoimmune diseases including systemic lupus erythematosus and related conditions, and renal cell carcinoma. Its lead candidates—ALLO-316 targeting CD70 for RCC and ALLO-329 targeting both CD19 and CD70 for autoimmune indications—represent attempts to broaden the addressable market for cell-based immunotherapy beyond the narrow population that benefits from approved autologous CAR T products.
Allogene operates as a pre-commercial biotech with no marketed products and revenues dependent on milestone payments, research collaborations, and capital raises. The company has funded operations through venture capital and public equity offerings; in recent years it conducted an underwritten public offering raising over $200 million. As a public company, it files 10-K reports with the SEC and operates under the regulatory framework governing clinical-stage biopharmaceutical development.
Pipeline and Therapeutic Focus
The company’s work breaks down across therapeutic programs rather than traditional revenue-generating business units:
| Program | Target | Indication(s) | Status |
|---|---|---|---|
| ALLO-316 | CD70 | Renal cell carcinoma | Clinical development |
| ALLO-329 | CD19/CD70 | Autoimmune diseases (SLE, IIM, SSc) | Clinical development |
| Other pipeline | Multiple targets | LBCL and emerging indications | Preclinical to early clinical |
Allogene’s capital structure depends entirely on external funding—public markets stock offerings, debt, and potential partnerships. Its burn rate is typical for cell-therapy development: substantial preclinical R&D costs, clinical trial expenses, manufacturing scale-up, and regulatory submissions. Success in the category has been limited; allogeneic CAR T remains more difficult to manufacture and preserve than anticipated when the company was founded, creating a persistent challenge to commercialization timelines and investor confidence.